SCHEMBL6312652

SCHEMBL6312652

CCc1c(C(=O)OC)cnn1-c1ccc2[nH]c(C)nc2c1

nearest known ligand 0.45

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 18/20 0.45
FGFR2 P21802 18/20 0.45
FGFR3 P22607 18/20 0.45
KDM4E B2RXH2 1/20 0.43
MAPT P10636 1/20 0.43
ALOX15 P16050 1/20 0.43
TSHR P16473 1/20 0.43
SRC P12931 2/20 0.42
FGFR4 P22455 2/20 0.42
KDR P35968 2/20 0.42
KCNH2 Q12809 2/20 0.42
PDXK O00764 1/20 0.42
EPHB6 O15197 1/20 0.42
RET P07949 1/20 0.42
MAPKAPK2 P49137 1/20 0.42
HDAC6 Q9UBN7 1/20 0.42
NR4A3 Q92570 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6312659 0.92 FGFR1 (0.52) FGFR1FGFR2FGFR3SRCFGFR4
SCHEMBL6313429 0.88 NR4A3 (0.56) FGFR1FGFR2FGFR3SRCFGFR4
SCHEMBL4454442 0.83 FGFR1 (0.42) FGFR1FGFR2FGFR3SRCFGFR4
SCHEMBL4454445 0.82 SLC9A1 (0.44) FGFR1FGFR2FGFR3SRCFGFR4
Hydrochloric Acid SCHEMBL6320000 0.82 FGFR1 (0.42) FGFR1FGFR2FGFR3SRCFGFR4
SCHEMBL6315637 0.82 NR4A3 (0.43) FGFR1FGFR2FGFR3KDM4EMAPT
SCHEMBL6320056 0.82 NR4A3 (0.43) FGFR1FGFR2FGFR3KDM4EMAPT
Hydrochloric Acid SCHEMBL6320007 0.82 SLC9A1 (0.43) FGFR1FGFR2FGFR3SRCFGFR4
SCHEMBL6321499 0.81 KMT2A (0.46) KDM4EMAPTALOX15TSHRNR4A3
SCHEMBL6313435 0.79 NR4A3 (0.56) FGFR1FGFR2FGFR3SRCFGFR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6974813-B2 N-[(substituted five-membered di-or triaza diunsaturated ring) carbonyl] guanidine derivatives for the treatment of ischemia WARNER-LAMBERT COMPANY (US) 2005-12-13 US disclosed
US-20030149043-A1 N-[(substituted five-membered di-or triaza diunsaturated ring)carbonyl] guanidine derivatives for the treatment of ischemia PFIZER INC. 2003-08-07 US disclosed
US-6492401-B1 SODIUM HYDROGEN EXCHANGER TYPE 1 INHIBITORS; REDUCING PERIOPERATIVE MYOCARDIAL TISSUE DAMAGE PFIZER, INC. 2002-12-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030149043-A1 N-[(substituted five-membered di-or triaza diunsaturated ring)carbonyl] guanidine derivatives for the treatment of ischemia NHERF1, SLC28A1, TNNI3 FGFR1 2482/4885FGFR2 4370/4885FGFR3 3975/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.